Inventor · disambiguated record
Lila Drittanti
Also filed as: DRITTANTI LILA
15 granted patents·20 pending applications·231 citations·filing 2001–2025
94Inventor score
Top patents by PatentIndex Score
35 records- 0194US7650243B2Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid moleculesHANALL PHARMACEUTICAL CO LTD·Filed 2007·Granted Jan 19, 2010·39 cites·19 claims
- 0292US7998469B2Protease resistant interferon beta mutantsHANALL BIOPHARMA CO LTD·Filed 2007·Granted Aug 16, 2011·14 cites·11 claims
- 0392US7611700B2Protease resistant modified interferon alpha polypeptidesHANALL PHARMACEUTICALS CO LTD·Filed 2003·Granted Nov 3, 2009·34 cites·24 claims
- 0491US8052964B2Interferon-β mutants with increased anti-proliferative activityHANALL BIOPHARMA CO LTD·Filed 2008·Granted Nov 8, 2011·11 cites·12 claims
- 0590US7884073B2Modified growth hormoneHANALL BIOPHARMA CO LTD·Filed 2006·Granted Feb 8, 2011·14 cites·32 claims
- 0690US7647184B2High throughput directed evolution by rational mutagenesisHANALL PHARMACEUTICALS CO LTD·Filed 2001·Granted Jan 12, 2010·36 cites·26 claims
- 0789US8383388B2Modified coagulation factor IX polypeptides and use thereof for treatmentCATALYST BIOSCIENCES INC·Filed 2007·Granted Feb 26, 2013·22 cites·65 claims
- 0889US7998930B2Modified growth hormonesHANALL BIOPHARMA CO LTD·Filed 2005·Granted Aug 16, 2011·13 cites·12 claims
- 0987US8222209B2Modified growth hormones that exhibit increased protease resistance and pharmaceutical compositions thereofGUYON THIERRY·Filed 2011·Granted Jul 17, 2012·12 cites·17 claims
- 1086US8252743B2Modified erythropoietin polypeptides and uses thereof for treatmentGUYON THIERRY·Filed 2007·Granted Aug 28, 2012·16 cites·27 claims
- 1184US8057787B2Protease resistant modified interferon-beta polypeptidesGANTIER RENE·Filed 2008·Granted Nov 15, 2011·4 cites·13 claims
- 1284US7635679B2Protease resistant mutant of human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A)CREABILIS THERAPEUTICS SPA·Filed 2007·Granted Dec 22, 2009·11 cites·3 claims
- 1382US8114839B2Protease resistant modified erythropoietin polypeptidesGANTIER RENE·Filed 2008·Granted Feb 14, 2012·3 cites·23 claims
- 1478US8105573B2Protease resistant modified IFN beta polypeptides and their use in treating diseasesGANTIER RENE·Filed 2011·Granted Jan 31, 2012·2 cites·4 claims
- 1573US2025108080A1Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and usesAGS THERAPEUTICS SAS·Filed 2024·Application pending·0 cites
- 1668US2024423923A1Extracellular vesicles from microalgae, their biodistribution upon administration, and usesAGS THERAPEUTICS SAS·Filed 2024·Application pending·0 cites
- 1764US2024173265A1Extracellular vesicles from microalgae, their preparation, and usesAGS THERAPEUTICS SAS·Filed 2024·Application pending·0 cites
- 1864US2008159977A1Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid moleculesGANTIER RENE·Filed 2007·Application pending·0 cites
- 1963US2008194477A1Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid moleculesGANTIER RENE·Filed 2007·Application pending·0 cites
- 2063US2008075672A1Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid moleculesGANTIER RENE·Filed 2007·Application pending·0 cites
- 2162US2007254838A1Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid moleculesGANTIER RENE·Filed 2007·Application pending·0 cites
- 2259US2005202438A1Rational directed protein evolution using two-dimensional rational mutagenesis scanningFiled 2003·Application pending·0 cites
- 2359US2006020116A1Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid moleculesGANTIER RENE·Filed 2005·Application pending·0 cites
- 2456US8058232B2HMGB1 high affinity binding domain Box-A mutantsFUMERO SILVANO·Filed 2009·Granted Nov 15, 2011·0 cites·5 claims
- 2553US2025339483A1Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereofAGS THERAPEUTICS SAS·Filed 2025·Application pending·0 cites
- 2652US2008003202A1Modified interferon-beta (IFN-beta) polypeptidesGUYON THIERRY·Filed 2007·Application pending·0 cites
- 2752US2008038224A1Modified interferon-beta (IFN-beta) polypeptidesGUYON THIERRY·Filed 2007·Application pending·0 cites
- 2849US2012264686A9Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereofGUYON THIERRY·Filed 2009·Application pending·0 cites
- 2949US2006020396A1Rational directed protein evolution using two-dimensional rational mutagenesis scanningGANTIER RENE·Filed 2005·Application pending·0 cites
- 3049US2003224404A1High throughput directed evolution of nucleic acids by rational mutagenesisFiled 2003·Application pending·0 cites
- 3145US2008260820A1Oral dosage formulations of protease-resistant polypeptidesBORRELLY GILLES·Filed 2007·Application pending·0 cites
- 3244US2013243855A1Modified coagulation factor IX polypeptides and use thereof for treatmentOYHENART JORGE·Filed 2012·Application pending·0 cites
- 3343US2006251619A1Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptidesBORRELLY GILLES·Filed 2006·Application pending·0 cites
- 3440US2003129203A1Mutant recombinant adeno-associated virusesNAUTILUS BIOTECH S A·Filed 2001·Application pending·0 cites
- 3534US2013130263A1Gametes separation methods, compositions and uses thereofVEGA MANUEL·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lila Drittanti files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →